# Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.

> **NCT06000514** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hospital Universitário Professor Edgard Santos** · enrollment: 20 (actual)

## Conditions studied

- Cutaneous Leishmaniasis, American

## Interventions

- **DRUG:** Sm29 Protein, Schistosoma Mansoni
- **DRUG:** Pentavalent antimony (Sbv)

## Key facts

- **NCT ID:** NCT06000514
- **Lead sponsor:** Hospital Universitário Professor Edgard Santos
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2022-04-06
- **Final completion:** 2022-07-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-08-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06000514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06000514, "Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06000514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*